A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma
To evaluate the efficacy and safety of Cadonilimab Injection in combination with Regorafenib in the treatment of intermediate to advanced hepatocellular carcinoma that has failed at least one prior systemic therapy .
Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy
DRUG: Cadonilimab Injection|DRUG: Regorafenib
Overall response rate ( ORR), Defined as proportion of patients who have a best response of CR or PR, up to 1 years|Overall survival (OS), OS is defined as the time from date of neoadjuvant treatment start to the date of death from any cause or to the date of last follow-up if patients are alive. If a patient is alive by the time of final analysis, the patient will be censored at the last follow-up date., up to 3 years|Progress Free Survival （PFS）, Defined as the time from enrollment to disease progression or death (whichever occurs first), up to 3 years|Adverse Events (AEs), Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0, up to 3 years
An open, single-arm, single-centre clinical study evaluating Cadonilimab Injection in combination with Regorafenib for the treatment of intermediate to advanced hepatocellular carcinoma that has failed at least one prior systemic therapy.